Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | TGTX |
---|---|---|
09:32 ET | 21588 | 27.39 |
09:33 ET | 11971 | 27.21 |
09:35 ET | 29098 | 27.06 |
09:37 ET | 11159 | 27.2963 |
09:39 ET | 21240 | 27.46 |
09:42 ET | 41515 | 27.55 |
09:44 ET | 12824 | 27.57 |
09:46 ET | 6013 | 27.5759 |
09:48 ET | 14987 | 27.71 |
09:50 ET | 13383 | 27.68 |
09:51 ET | 14034 | 27.73 |
09:53 ET | 6488 | 27.59 |
09:55 ET | 7941 | 27.4177 |
09:57 ET | 6193 | 27.44 |
10:00 ET | 10936 | 27.51 |
10:02 ET | 7762 | 27.67 |
10:04 ET | 30022 | 27.745 |
10:06 ET | 19284 | 27.725 |
10:08 ET | 14118 | 27.7436 |
10:09 ET | 8455 | 27.66 |
10:11 ET | 16787 | 27.75 |
10:13 ET | 13064 | 27.7 |
10:15 ET | 11141 | 27.665 |
10:18 ET | 4973 | 27.505 |
10:20 ET | 9262 | 27.415964 |
10:22 ET | 13479 | 27.57 |
10:24 ET | 6108 | 27.53 |
10:26 ET | 9824 | 27.49 |
10:27 ET | 4204 | 27.56 |
10:29 ET | 5955 | 27.68 |
10:31 ET | 10912 | 27.6383 |
10:33 ET | 9828 | 27.69 |
10:36 ET | 8481 | 27.68 |
10:38 ET | 6230 | 27.71 |
10:40 ET | 9245 | 27.74 |
10:42 ET | 3820 | 27.7 |
10:44 ET | 6399 | 27.73 |
10:45 ET | 14389 | 27.83 |
10:47 ET | 26487 | 27.7454 |
10:49 ET | 10603 | 27.8 |
10:51 ET | 10439 | 27.88 |
10:54 ET | 6150 | 27.81 |
10:56 ET | 8910 | 27.785 |
10:58 ET | 13068 | 27.6862 |
11:00 ET | 6702 | 27.63 |
11:02 ET | 9219 | 27.6931 |
11:03 ET | 4394 | 27.63 |
11:05 ET | 400 | 27.66 |
11:07 ET | 8930 | 27.63 |
11:09 ET | 5981 | 27.76 |
11:12 ET | 6279 | 27.75 |
11:14 ET | 6500 | 27.7315 |
11:16 ET | 1391 | 27.74 |
11:18 ET | 2471 | 27.75 |
11:20 ET | 4477 | 27.7 |
11:21 ET | 1679 | 27.73 |
11:23 ET | 6625 | 27.72 |
11:25 ET | 5286 | 27.645 |
11:27 ET | 2752 | 27.67 |
11:30 ET | 300 | 27.66 |
11:32 ET | 2442 | 27.696 |
11:34 ET | 6389 | 27.7 |
11:36 ET | 8174 | 27.61 |
11:38 ET | 8238 | 27.56 |
11:39 ET | 100 | 27.59 |
11:41 ET | 57618 | 27.565 |
11:43 ET | 6978 | 27.54 |
11:45 ET | 17041 | 27.5499 |
11:48 ET | 3558 | 27.565 |
11:50 ET | 861 | 27.555 |
11:52 ET | 514 | 27.56 |
11:54 ET | 3700 | 27.57 |
11:56 ET | 5300 | 27.555 |
11:57 ET | 4401 | 27.55 |
11:59 ET | 300 | 27.5588 |
12:01 ET | 5797 | 27.49 |
12:03 ET | 2400 | 27.47 |
12:06 ET | 8429 | 27.492 |
12:08 ET | 3142 | 27.55 |
12:10 ET | 5214 | 27.58 |
12:12 ET | 1255 | 27.575 |
12:14 ET | 1603 | 27.59 |
12:15 ET | 4937 | 27.6 |
12:17 ET | 3693 | 27.595 |
12:19 ET | 918 | 27.592 |
12:21 ET | 1422 | 27.59 |
12:24 ET | 3069 | 27.62 |
12:26 ET | 8173 | 27.705 |
12:28 ET | 1552 | 27.6901 |
12:30 ET | 2804 | 27.715 |
12:32 ET | 3492 | 27.77 |
12:33 ET | 6600 | 27.76 |
12:35 ET | 6052 | 27.775 |
12:37 ET | 1014 | 27.77 |
12:39 ET | 28828 | 27.885 |
12:42 ET | 1480 | 27.84 |
12:44 ET | 1517 | 27.85 |
12:46 ET | 4000 | 27.84 |
12:48 ET | 3071 | 27.83 |
12:50 ET | 3764 | 27.7463 |
12:51 ET | 1744 | 27.745 |
12:53 ET | 2330 | 27.73 |
12:55 ET | 2051 | 27.72 |
12:57 ET | 573 | 27.72 |
01:00 ET | 1900 | 27.74 |
01:02 ET | 4913 | 27.77 |
01:04 ET | 550 | 27.775 |
01:06 ET | 10207 | 27.77 |
01:08 ET | 2300 | 27.74 |
01:09 ET | 400 | 27.735 |
01:11 ET | 2974 | 27.721 |
01:13 ET | 14200 | 27.7 |
01:15 ET | 5053 | 27.675 |
01:18 ET | 1616 | 27.67 |
01:20 ET | 3410 | 27.6304 |
01:22 ET | 2440 | 27.66 |
01:24 ET | 3284 | 27.6999 |
01:26 ET | 1300 | 27.68 |
01:27 ET | 9078 | 27.7199 |
01:29 ET | 6985 | 27.752569 |
01:31 ET | 1130 | 27.76 |
01:33 ET | 6988 | 27.83 |
01:36 ET | 5120 | 27.83 |
01:38 ET | 6886 | 27.87 |
01:40 ET | 71968 | 27.91 |
01:42 ET | 11861 | 27.846791 |
01:44 ET | 2870 | 27.815 |
01:45 ET | 2565 | 27.83 |
01:47 ET | 11699 | 27.76 |
01:49 ET | 3168 | 27.79 |
01:51 ET | 1666 | 27.81 |
01:54 ET | 9138 | 27.92 |
01:56 ET | 6892 | 27.98 |
01:58 ET | 3716 | 27.97 |
02:00 ET | 7305 | 27.97 |
02:02 ET | 7816 | 27.95 |
02:03 ET | 3056 | 27.95 |
02:05 ET | 4263 | 27.88 |
02:07 ET | 3800 | 27.88 |
02:09 ET | 3024 | 27.94 |
02:12 ET | 10326 | 27.89 |
02:14 ET | 6132 | 27.965 |
02:16 ET | 3363 | 27.94 |
02:18 ET | 17985 | 27.915 |
02:20 ET | 2562 | 27.96 |
02:21 ET | 2919 | 27.95 |
02:23 ET | 5206 | 27.93 |
02:25 ET | 3149 | 27.965 |
02:27 ET | 89382 | 28.065 |
02:30 ET | 18189 | 28.03 |
02:32 ET | 8266 | 28 |
02:34 ET | 22514 | 28.13 |
02:36 ET | 4400 | 28.13 |
02:38 ET | 13485 | 28.2 |
02:39 ET | 9076 | 28.2 |
02:41 ET | 10340 | 28.17 |
02:43 ET | 8851 | 28.1703 |
02:45 ET | 18659 | 28.055 |
02:48 ET | 29442 | 28 |
02:50 ET | 15800 | 27.92 |
02:52 ET | 16196 | 28.135 |
02:54 ET | 13886 | 28.1132 |
02:56 ET | 7901 | 27.9 |
02:57 ET | 57236 | 27.95 |
02:59 ET | 6568 | 28.025 |
03:01 ET | 19402 | 28.06 |
03:03 ET | 22081 | 28.1 |
03:06 ET | 7279 | 28.14 |
03:08 ET | 7561 | 28.2 |
03:10 ET | 10642 | 28.09 |
03:12 ET | 5956 | 28.195 |
03:14 ET | 31550 | 28.39 |
03:15 ET | 12242 | 28.34 |
03:17 ET | 4416 | 28.335 |
03:19 ET | 3854 | 28.33 |
03:21 ET | 5350 | 28.33 |
03:24 ET | 10974 | 28.36 |
03:26 ET | 12868 | 28.33 |
03:28 ET | 4840 | 28.37 |
03:30 ET | 9684 | 28.31 |
03:32 ET | 16301 | 28.24 |
03:33 ET | 9536 | 28.21 |
03:35 ET | 15689 | 28.2 |
03:37 ET | 7023 | 28.1 |
03:39 ET | 9118 | 28.02 |
03:42 ET | 13685 | 28 |
03:44 ET | 28445 | 27.99 |
03:46 ET | 11628 | 28 |
03:48 ET | 11271 | 28.02 |
03:50 ET | 10716 | 28.05 |
03:51 ET | 23678 | 28 |
03:53 ET | 15879 | 27.93 |
03:55 ET | 27874 | 27.991 |
03:57 ET | 42631 | 27.93 |
04:00 ET | 379984 | 27.9 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
TG Therapeutics Inc | 4.2B | -261.5x | --- |
Axsome Therapeutics Inc | 4.4B | -13.9x | --- |
ADMA Biologics Inc | 4.6B | 140.2x | --- |
Denali Therapeutics Inc | 4.2B | -10.7x | --- |
CRISPR Therapeutics AG | 4.3B | -18.5x | --- |
Alvotech SA | 3.8B | -4.8x | --- |
TG Therapeutics, Inc. is a fully integrated, commercial stage, biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. Its clinical drug candidates include Ublituximab (anti-CD20 mAb), TG-1701 (BTK inhibitor) and TG-1801 (anti-CD47/CD19 bispecific mAb). BRIUMVI is an anti-CD20 monoclonal antibody for the treatment of RMS, which include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. TG-1701 is a novel, orally available and covalently bound Bruton’s tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in in vitro kinase screening. TG-1801 is a bispecific CD47 and CD19 antibody. It is the therapy to target both CD19, a B-cell specific market expressed across B-cell malignancies, and CD47. It also evaluates complementary products, technologies and companies for in-licensing, partnership, acquisition and/or investment opportunities.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $4.2B |
---|---|
Revenue (TTM) | $264.8M |
Shares Outstanding | 154.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 2.17 |
EPS | $-0.11 |
Book Value | $1.06 |
P/E Ratio | -261.5x |
Price/Sales (TTM) | 15.9 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -0.19% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.